{
    "2018-02-15": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Q4",
                        "Revenues",
                        "Jakafi",
                        "Sales"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "VEA, NSRGY, NVS, TM: ETF Inflow Alert",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflow",
                        "NSRGY",
                        "NVS"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "ETFs",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva",
                "features": {
                    "keywords": [
                        "Intercept",
                        "Q4",
                        "Earnings",
                        "Sales",
                        "Ocaliva"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "3 Tough Questions for Amgen",
                "features": {
                    "keywords": [
                        "Amgen",
                        "Questions"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Keytruda: Merck’s Largest Revenue Contributor in 4Q17",
                "features": {
                    "keywords": [
                        "Keytruda",
                        "Merck",
                        "Revenue",
                        "4Q17"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Acquisition",
                        "Targets"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "The Swiss Stock Market Inched Higher As Nestlé Weighs",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market",
                        "Nestlé"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "consumer goods"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Nestle FY Profit Down; to Explore Strategic Options For Its Gerber Life Insurance",
                "features": {
                    "keywords": [
                        "Nestle",
                        "FY",
                        "Profit",
                        "Gerber",
                        "Life",
                        "Insurance"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "consumer goods",
                        "insurance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Roche's Rituxan Gets Priority Review for Label Expansion",
                "features": {
                    "keywords": [
                        "Roche",
                        "Rituxan",
                        "Priority",
                        "Review",
                        "Label",
                        "Expansion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}